Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
80 participants
INTERVENTIONAL
2020-11-25
2021-12-15
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Effects of Vitamin D3 Alone and in a Combination With Omega-3 on the Association of C-peptide With Glycemic Control
NCT04307784
Effect of Vitamin d and Omega 3 on Osteocalcin
NCT04005612
The Combined Effect of Omega-3 Fatty Acid and Vitamin D3 on Lipid Profile Levels and Oxidized Low Density Lipoprotein
NCT04005573
Effect of Vitamin D3 and Omega-3FA on Leptin and HbA1C With Vitamin D Deficiency
NCT03735303
Effect of Vitamin D3 and Omega-3FA on Estradiol
NCT03333564
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
This study was designed to investigate whether omega 3 supplementation has a potential effect on the reducing of serum 25-hydroxyvitamin D levels.
This randomized, placebo-controlled clinical trial (RCT) was designed to evaluate 300 mg omega-3FA daily for 2 months on serum levels of 25-hydroxyvitamin D levels. This RCT will be conducted on 80 to 90 Jordanian men and women aged 22 to 66 years. Baseline and follow-up levels for 25-hydroxyvitamin D (25OHD), parathyroid hormone (PTH), calcium, phosphate, liver and kidney functions will be assayed.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
BASIC_SCIENCE
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Omega3-FA group
Omega3-FA group 1000 mg wild salmon and fish oil complex (contains 300 mg of omega3-FA) once daily
Dietary Supplement: Omega3-FA
Dietary Supplement: Omega3-FA 300 mg of omega3-FA once daily for 8 weeks
Control group
VD3 group 50,000 IU/week
Dietary Supplement: Omega3-FA
Dietary Supplement: Omega3-FA 300 mg of omega3-FA once daily for 8 weeks
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Dietary Supplement: Omega3-FA
Dietary Supplement: Omega3-FA 300 mg of omega3-FA once daily for 8 weeks
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Male and female Jordanian ASU students and employees who live in Amman.
Informed written consent from the participant prior to the start of the study.
a serum 25(OH)D concentration between 10 and 70 ng/mL.
Exclusion Criteria
Men or women previously diagnosed with chronic diseases, including kidney disease or GIT problems.
Who are receiving vitamin D3 supplements (3 months before the start of the study) .
Pregnants,Breastfeeding females ,Females using hormonal contraceptives
22 Years
66 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Applied Science Private University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Mahmoud Suleiman Abu-Samak
Prof.Dr. Mahmoud Suleiman Abu-Samak
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Mahmoud S Abu-Samak, PhD
Role: PRINCIPAL_INVESTIGATOR
Department of Clinical Pharmacy and Therapeutics
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Mahmoud S Abu-Samak
Amman, , Jordan
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
DRGS-2014-2015-165-5
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.